EUVIMEDEUVIMED entdecken
Crossref

HDAC6 inhibition upregulates endothelial SOD3 expression via Sp1 acetylation and attenuates angiotensin II ‐induced hypertension

Zhexi Chi, Van Quan Do, Rukhsana Kausar, Hyun Kyung Kim, Nga Thi Thanh Nguyen, Truc Phan Hoang Le, Jungwoo Lee, In-Jeoung Baek, Sang-Wook Lee, Jae Hyung Kim iD, Sang Yoon Lee iD

The FEBS Journal · 2025-05 · 292 (10) · 2624-2644

DOI: 10.1111/febs.70026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, online erschienen am 16.02.2025. Verfasst von Zhexi Chi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Pain Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea. Hauptthemen laut MEDLINE: Angiotensin II, Histone Deacetylase 6, Sp1 Transcription Factor, Superoxide Dismutase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extracellular superoxide dismutase (SOD3) plays an important role in maintaining vascular redox homeostasis by eliminating superoxides. The angiotensin II (AngII) peptide mediates vasoconstriction in part via reactive oxygen species (ROS) but has pathologic effects when elevated in adults. Histone deacetylase 6 (HDAC6) modulates the acetylation of non‐histone substrates and is associated with hypertensive disorders. Here, we investigated the potential regulation of SOD3 by HDAC6 in human aortic endothelial cells (HAECs) and its implications for AngII‐induced oxidative stress and hypertension. HDAC6 inhibition (via the specific inhibitor tubastatin A (TubA), gene knockdown, or a deacetylase activity‐deficient mutant) significantly increased SOD3 protein and mRNA expression but did not affect SOD1 or SOD2 protein levels. Conversely, AngII downregulated SOD3 levels and increased ROS and superoxide levels; these effects were antagonized by TubA. We confirmed that the transcription factor Sp1 mediates TubA‐induced as well as basal SOD3 expression. Notably, TubA strongly augmented Sp1 acetylation at lysine 703, which activated Sp1 binding to the proximal SOD3 promoter region and, consequently, SOD3 expression. Alternatively, AngII decreased Sp1 acetylation, and TubA‐mediated SOD3 induction was reduced upon overexpression of an acetylation‐resistant Sp1 mutant (K703R) compared to that by the wild‐type protein. Consistent with these findings, aortic SOD3 expression was significantly higher in HDAC6‐deficient mice than in wild‐type mice. Moreover, AngII infusion‐mediated blood pressure elevation was reduced in HDAC6‐deficient mice compared with that in wild‐type mice. Collectively, our results suggest that HDAC6 inhibition leads to SOD3 upregulation by enhancing Sp1 acetylation in HAECs, thereby mitigating AngII‐induced oxidative stress and hypertension.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin IIHistone Deacetylase 6Sp1 Transcription FactorSuperoxide DismutaseHypertensionAnimalsAcetylationHumansMiceReactive Oxygen SpeciesEndothelial CellsOxidative StressHydroxamic AcidsHistone Deacetylase InhibitorsUp-RegulationMice, Inbred C57BLMalePromoter Regions, GeneticIndoles

Stichwörter der Autor:innen

HDAC6SOD3Sp1angiotensin IItubastatin A

Substanzen

Angiotensin IIHistone Deacetylase 6Sp1 Transcription FactorSuperoxide DismutaseReactive Oxygen SpeciesSOD3 protein, humanHDAC6 protein, humantubastatin AHdac6 protein, mouseHydroxamic Acids

Autor:innen und Institutionen

  • Department of Anesthesiology and Pain Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.
  • Institute of Medical Science, Ajou University School of Medicine, Suwon, Korea.
  • Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea.
  • Department of Cell and Genetic Engineering, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

ORCID-Profile: Jae Hyung Kim, Sang Yoon Lee

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Chi, Z., Do, V. Q., Kausar, R., Kim, H. K., Nguyen, N. T. T., Le, T. P. H., Lee, J., Baek, I. J., Lee, S. W., Kim, J. H., & Lee, S. Y. (2025). HDAC6 inhibition upregulates endothelial SOD3 expression via Sp1 acetylation and attenuates angiotensin II ‐induced hypertension. The FEBS Journal, 292(10), 2624-2644. https://doi.org/10.1111/febs.70026

Vancouver

Chi Z, Do VQ, Kausar R, Kim HK, Nguyen NTT, Le TPH, et al. HDAC6 inhibition upregulates endothelial SOD3 expression via Sp1 acetylation and attenuates angiotensin II ‐induced hypertension. The FEBS Journal. 2025;292(10):2624-2644. doi:10.1111/febs.70026

BibTeX
@article{Chi2025,
  author = {Chi, Zhexi and Do, Van Quan and Kausar, Rukhsana and Kim, Hyun Kyung and Nguyen, Nga Thi Thanh and Le, Truc Phan Hoang and Lee, Jungwoo and Baek, In-Jeoung and Lee, Sang-Wook and Kim, Jae Hyung and Lee, Sang Yoon},
  title = {HDAC6 inhibition upregulates endothelial SOD3 expression via Sp1 acetylation and attenuates angiotensin II ‐induced hypertension},
  journal = {The FEBS Journal},
  year = {2025},
  volume = {292},
  number = {10},
  pages = {2624--2644},
  doi = {10.1111/febs.70026}
}
Kostenlos starten →